S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:CATSCatasys Stock Price, Forecast & News

$25.89
0.00 (0.00 %)
(As of 07/16/2020)
Add
Compare
Today's Range
$25.05
Now: $25.89
$26.62
50-Day Range
$20.95
MA: $25.33
$27.77
52-Week Range
$8.55
Now: $25.89
$32.55
Volume319,900 shs
Average Volume325,358 shs
Market Capitalization$440.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.22
Catasys, Inc. provides big data predictive analytics, artificial intelligence and telehealth, combined with human intervention services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. The company's OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services. Its OnTrak solution combines medical and psychosocial treatments with elements of traditional disease management, case management, and ongoing member support to help organizations treat and manage populations struggling with substance dependence, depression, and anxiety to improve their health and thereby decrease their health care costs. Catasys, Inc.'s OnTrak solution includes various components, such as identification of impactable members, member engagement, enrollment/referral, provider network, outpatient medical treatment, outpatient psychosocial treatment, care coaching, monitoring and reporting, and proprietary Web-based clinical information platform. The company was formerly known as Hythiam, Inc. and changed its name to Catasys, Inc. in March 2011. Catasys, Inc. was founded in 2000 and is based in Los Angeles, California.
Read More
Catasys logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CATS
Previous SymbolOTCMKTS:CATS
CUSIPN/A
Phone310-444-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.10 million
Book Value($1.44) per share

Profitability

Net Income$-25,660,000.00

Miscellaneous

EmployeesN/A
Market Cap$440.65 million
Next Earnings DateN/A
OptionableNot Optionable
$25.89
0.00 (0.00 %)
(As of 07/16/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive CATS News and Ratings via Email

Sign-up to receive the latest news and ratings for CATS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catasys (NASDAQ:CATS) Frequently Asked Questions

How has Catasys' stock price been impacted by COVID-19 (Coronavirus)?

Catasys' stock was trading at $13.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CATS stock has increased by 96.6% and is now trading at $25.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Catasys?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catasys in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Catasys
.

How were Catasys' earnings last quarter?

Catasys, Inc. (NASDAQ:CATS) announced its earnings results on Thursday, May, 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.04. The business had revenue of $12.34 million for the quarter.
View Catasys' earnings history
.

What price target have analysts set for CATS?

2 brokers have issued 12-month price targets for Catasys' stock. Their forecasts range from $26.00 to $35.00. On average, they expect Catasys' share price to reach $30.50 in the next twelve months. This suggests a possible upside of 17.8% from the stock's current price.
View analysts' price targets for Catasys
.

Has Catasys been receiving favorable news coverage?

News coverage about CATS stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Catasys earned a coverage optimism score of -1.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Catasys
.

Are investors shorting Catasys?

Catasys saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,430,000 shares, an increase of 19.9% from the April 30th total of 2,860,000 shares. Based on an average trading volume of 438,700 shares, the days-to-cover ratio is currently 7.8 days. Currently, 50.2% of the shares of the stock are short sold.
View Catasys' Short Interest
.

Who are some of Catasys' key competitors?

What other stocks do shareholders of Catasys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catasys investors own include NVIDIA (NVDA), Inseego (INSG), Alibaba Group (BABA), Alteryx (AYX), Crispr Therapeutics (CRSP), Micron Technology (MU), InVitae (NVTA), QUALCOMM (QCOM), Editas Medicine (EDIT) and Marvell Technology Group (MRVL).

Who are Catasys' key executives?

Catasys' management team includes the following people:
  • Mr. Terren S. Peizer, Founder, Chairman & CEO (Age 59)
  • Mr. Richard A. Anderson, Pres & COO (Age 50)
  • Mr. Christopher L. Shirley, Chief Financial Officer (Age 43)
  • Mr. Michael E. Green, Director of Bus. Devel.
  • Mr. Jeremiah Stone, Chief Technology Officer

What is Catasys' stock symbol?

Catasys trades on the NASDAQ under the ticker symbol "CATS."

Who are Catasys' major shareholders?

Catasys' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (2.45%), Janney Montgomery Scott LLC (0.87%), Uniplan Investment Counsel Inc. (0.82%), Great Lakes Advisors LLC (0.62%), Taylor Wealth Management Partners (0.52%) and Bank of New York Mellon Corp (0.20%). Company insiders that own Catasys stock include Curtis Medeiros and David E Smith.
View institutional ownership trends for Catasys
.

Which major investors are selling Catasys stock?

CATS stock was sold by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc., Janney Montgomery Scott LLC, UBS Group AG, Taylor Wealth Management Partners, and Ancora Advisors LLC.
View insider buying and selling activity for Catasys
.

Which major investors are buying Catasys stock?

CATS stock was acquired by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Great Lakes Advisors LLC, Swiss National Bank, QV Investors Inc., Bank of New York Mellon Corp, Integrated Advisors Network LLC, Bank of America Corp DE, and SG Americas Securities LLC.
View insider buying and selling activity for Catasys
.

How do I buy shares of Catasys?

Shares of CATS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catasys' stock price today?

One share of CATS stock can currently be purchased for approximately $25.89.

How big of a company is Catasys?

Catasys has a market capitalization of $440.65 million and generates $35.10 million in revenue each year. The company earns $-25,660,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

What is Catasys' official website?

The official website for Catasys is www.catasys.com.

How can I contact Catasys?

Catasys' mailing address is 11601 WILSHIRE BOULEVARD SUITE 1100, LOS ANGELES CA, 90025. The company can be reached via phone at 310-444-4300 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.